| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 02/27/2003 | US20030040499 Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-beta (TGF-beta) |
| 02/27/2003 | US20030040498 Contacting the tumor cell with a replicon such that the replicon is taken up into tumor cell and tumor cell is killed |
| 02/27/2003 | US20030040497 Compositions and methods for non-parenteral delivery of oligonucleotides |
| 02/27/2003 | US20030040487 Polymer complexes of glucuronoglucanes |
| 02/27/2003 | US20030040482 For therapy of precocious puberty, prostate cancer, ovarian cancer, benign prostatic hypertrophy, endometriosis, uterine fibroids, breast cancer, premenstrual syndrome, polycystic ovary syndrome, disease caused by excesses of gonadal hormones |
| 02/27/2003 | US20030040111 Differentiated cells suitable for human therapy |
| 02/27/2003 | US20030040044 Anti-dual integrin antibodies, compositions, methods and uses |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039983 Nucleotide sequences coding polypeptide for use in the treatment, prevention and diagnosis of cancer |
| 02/27/2003 | US20030039959 Detection of premature tumor cells in mammary gland tissue; obtain mammary gland tissue, incubate with diagnostic agent, monitor sample for binding and signal, presence of signal indicates premature cancer |
| 02/27/2003 | US20030039860 Vacuum vapor deposition; metallization, alloying |
| 02/27/2003 | US20030039705 Triterpene compositions and methods for use thereof |
| 02/27/2003 | US20030039689 Prodrug in polymer matrix; insertion into body |
| 02/27/2003 | US20030039683 Multilayer binding; lamellar surface structure |
| 02/27/2003 | US20030039656 Modified reoviral therapy |
| 02/27/2003 | US20030039655 Novel engineered superantigen for human therapy |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039647 Tetraspan protein and uses thereof |
| 02/27/2003 | US20030039646 Receptor interacting protein, which binds to itself and to other intracellular modulatory proteins; treating tumor cells or HIV-infected cells |
| 02/27/2003 | US20030039640 Infecting cells with a retrovirus in the presence of an immobilized material including a ligand which bings to the cell and a ligand which binds to the retrovirus |
| 02/27/2003 | US20030039639 Isolated stromal cells for use in the treatment of diseases of the central nervous system |
| 02/27/2003 | US20030039629 Espression enhancer for protein synthesis inhibitory genes |
| 02/27/2003 | US20030039628 Treating cancer or viral diseases for enhancing T-cell proliferation by administering an effective amount compound that inhibits the production or release of intercellular reactive oxygen metabolites |
| 02/27/2003 | US20030039626 Fat-binding polymers |
| 02/27/2003 | US20030039611 Selectively binds to antigen to cause cell impairment |
| 02/27/2003 | CA2496542A1 Humanised baculovirus |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458625A1 Transporters and ion channels |
| 02/27/2003 | CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 02/27/2003 | CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | CA2457745A1 Combination therapy for the treatment of cancer |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457405A1 Compositions and methods relating to benzodiazepine compounds |
| 02/27/2003 | CA2457321A1 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | CA2457164A1 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells |
| 02/27/2003 | CA2457143A1 In situ immunization |
| 02/27/2003 | CA2457066A1 Human protooncogene kg-20 and protein encoded therein |
| 02/27/2003 | CA2457043A1 Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof |
| 02/27/2003 | CA2457008A1 Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin useful for the treatment of cancer and infectious disease |
| 02/27/2003 | CA2456988A1 Gas microsphere liposome composites |
| 02/27/2003 | CA2456985A1 2h-phthalazin-1-ones and methods for use thereof |
| 02/27/2003 | CA2456966A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456843A1 A purification process for large scale production of gc-globulin, product obtained thereby and their use in medicine |
| 02/27/2003 | CA2456746A1 Method for treating lung cancers |
| 02/27/2003 | CA2456551A1 Tumour inhibiting lanthanum compounds |
| 02/27/2003 | CA2456470A1 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | CA2456334A1 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/27/2003 | CA2456149A1 Recombinant conjugate polypeptides for photodynamic therapy |
| 02/27/2003 | CA2454860A1 Hybrid interferon/interferon tau proteins, compositions and methods of use |
| 02/27/2003 | CA2454756A1 Methods and compounds for the targeting of protein to exosomes |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | WO2003009870A1 Remedies for mammary cancer |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | WO2002018407A2 Antisense oligonucleotides against vanilloid receptor 1 |
| 02/26/2003 | EP1285967A2 Human retroviral packaging cell line |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285920A1 C10 Ester sustituted taxanes as antitumor agents |
| 02/26/2003 | EP1285919A1 C10 Carbonate substituted taxanes as antitumor agents |
| 02/26/2003 | EP1285918A1 C7 Ester substituted taxanes as antitumor agents |
| 02/26/2003 | EP1285914A1 Nr1h4 nuclear receptor binding compounds |
| 02/26/2003 | EP1285270A2 Method for identifying compounds for modulating the activity of a tumour suppressor protein |
| 02/26/2003 | EP1285092A2 Methods for drug discovery, disease treatment, and diagnosis using metabolomics |
| 02/26/2003 | EP1285087A2 Enzymatic assays for screening anti-cancer agents |
| 02/26/2003 | EP1285081A2 Improved methods of transfection |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285071A2 Novel dual oxidases as mitogenic and endocrine regulators |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1285059A2 Adjuvant preparation for the induction of specific immunity |
| 02/26/2003 | EP1285004A1 Synthetic peptides and uses therefore |
| 02/26/2003 | EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof |
| 02/26/2003 | EP1285000A2 Use of adnf for enhancing learning and memory |
| 02/26/2003 | EP1284997A2 Therapeutic compounds for ovarian cancer |
| 02/26/2003 | EP1284996A2 Therapeutic anti-melanoma compounds |
| 02/26/2003 | EP1284986A1 Javelinization of protein antigens to heat shock proteins |
| 02/26/2003 | EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 02/26/2003 | EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 02/26/2003 | EP1284963A1 Novel calcium receptor active molecules and method for preparing same |
| 02/26/2003 | EP1284959A1 Compounds for modulating the rage receptor |
| 02/26/2003 | EP1284958A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives |
| 02/26/2003 | EP1284952A1 Substituted chalcones as therapeutic compounds |
| 02/26/2003 | EP1284741A2 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
| 02/26/2003 | EP1284734A1 Protein kinase inhibitors |
| 02/26/2003 | EP1284730A1 Aralkyl ester soft drugs |
| 02/26/2003 | EP1284728A1 Pharmaceuticals for treating obesity |
| 02/26/2003 | EP1284727A1 Intracorporeal medicaments for photodynamic treatment of disease |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 02/26/2003 | EP1150976B1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP1011726B1 Fused imidazole derivatives for improving oral bioavailability of pharmaceutical agents |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0910407B1 Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| 02/26/2003 | EP0896544B1 Combination of a somatostatin analogue and a rapamycin |
| 02/26/2003 | EP0822986B1 Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 02/26/2003 | EP0770137B1 Improvements in production of proteins in host cells |
| 02/26/2003 | EP0759943B1 Monoclonal antibody specific for vascular endothelial cell antigen endoglyx-1, the antigen itself, and uses thereof |
| 02/26/2003 | EP0436717B1 System for use in a method of therapeutic or diagnostic treatment |